The White House has withdrawn Dr. Heidi Overton's nomination to be commissioner of the US Food and Drug Administration, a day before the Senate health committee was due to vote on her. The decision came on Tuesday evening, 17 November 2026, after weeks of doubts among Republican senators over her record on flavoured vapes and the abortion pill mifepristone. The FDA has not had a Senate-confirmed leader since Marty Makary was forced out in May, and Republicans now have only a few weeks of Senate control left to confirm anyone else.[1][2][4]
| Nominee | Dr. Heidi Overton, preventive medicine doctor and White House domestic policy official[1][4] |
|---|---|
| Post | Commissioner of Food and Drugs (FDA)[1][2] |
| Nominated | Summer 2026[2] |
| Hearing | September 2026, Senate HELP Committee[1] |
| Withdrawn | Tuesday 17 November 2026, evening[1][2] |
| Committee vote | Had been set for Wednesday 18 November[1][2][4] |
| Votes needed | 11 of 21 committee members[1] |
| Acting commissioner | Kyle Diamantas, since May 2026[2][6] |
| Reported alternative | Sen. Roger Marshall (R-Kan.)[2][6] |
What happened
A White House official confirmed on Tuesday that the administration was dropping Overton. Two sources told CBS News that the White House shared its decision that evening, while Republican whips were still trying to round up enough votes for her. Axios was first to report the news.[1][2]
The timing tells you how close it was. The Senate Health, Education, Labor and Pensions (HELP) Committee had put her nomination on its agenda for Wednesday morning, alongside a handful of other health officials. To send her to the full Senate she needed 11 votes on the 21-member committee. That meant she could not lose a single Republican if all the Democrats voted no, and CBS News reported that none of the Democrats were expected to back her.[1][3]
Earlier on Tuesday, Semafor reported that Republicans were already discussing Senator Roger Marshall as a replacement, citing four people familiar with the talks. A Trump administration official told Semafor that Marshall was "viewed as an alternative if Heidi can't make it through".[6] CBS News separately reported that the White House had started talking to other candidates, including people who could run the agency in an acting role and so skip Senate confirmation altogether.[2][3]
Why the nomination failed
There was no single reason. Overton was squeezed from two sides of her own party at once, and the clock was running out.[3][6]
The abortion pill
Anti-abortion Republicans wanted firm commitments on mifepristone, the pill used in more than half of US abortions. Senator Josh Hawley emerged as a skeptic after Overton sidestepped questions on a safety study of the drug that the administration has long promised. Susan B. Anthony Pro-Life America urged the Senate to delay her confirmation and wants the FDA to ban mail-order mifepristone.[3] The FDA is due to finish its safety review of the drug in March, which NBC News calls one of the most consequential decisions the agency faces.[1]
From the other direction, Senators Susan Collins and Lisa Murkowski, two Republicans who support abortion access, never said how they would vote. At the September hearing Murkowski asked Overton about political pressure over mifepristone and criticised her for not taking a clear position. NBC News notes that Overton had praised the Supreme Court's decision to overturn Roe v. Wade and has called for strict limits on medication abortion.[1][3]
The vape fight
The second problem was vaping. President Trump campaigned in 2024 on a promise to "save vaping", and Overton carried out his pro-vape policies while she worked on the White House Domestic Policy Council.[3] Calley Means, a former senior adviser to Health Secretary Robert F. Kennedy Jr. and a leading voice in the MAHA (Make America Healthy Again) movement, said she wrote a policy that relaxed standards for fruit-flavoured vapes, and he urged his followers to help block her. He told CBS's "Face the Nation" that she "was the biggest block to MAHA policies I encountered in the government".[3][5] STAT reported that posters calling her "Heidi Vaperton" had gone up around Washington.[5]
The vape issue is also why the job was open. Makary resigned in May after clashing with the White House over the decision to authorise several fruit-flavoured vaping products.[1][5] On 8 November he told CBS News that "big tobacco exploited their connections to administration and HHS officials to put repeated pressure on me to approve fruit-flavored vapes that appeal to children", adding: "I wouldn't do it."[3]
Experience and vaccines
Before the hearing, committee chairman Bill Cassidy wrote that he had "strong concerns" about her nomination because she had little experience running a large organisation.[1] He had also called her link to the administration's push to reduce childhood vaccine uptake "almost disqualifying". She stood beside Trump in the Oval Office this summer when he signed an executive order on vaccines and twice wrongly called the MMR vaccine "lethal".[3] Her defenders pointed to her medical training and to endorsements from two former FDA commissioners.[3]
What Bill Cassidy said
Cassidy, a physician who chairs the HELP Committee and leaves Congress in early January, said the White House gave up when it did not have to. "Tonight, the White House abandoned a viable confirmation path for Dr. Overton," he wrote on X. "My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk."[1][2][4]
He said the final sticking point was abortion: "pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues. The Administration withdrew Dr. Overton rather than make such commitments." He told CBS News he believed she would have passed the committee and the full Senate, and he added that "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."[1][2]
On "Face the Nation" two days earlier he had laid out the trade-off he saw: a run of short-term acting chiefs who "probably will have more influence from the secretary", or a permanent commissioner with "the ability to establish some independence".[2][3]
Who is Heidi Overton?
Overton is a preventive medicine doctor who works as a domestic policy official in the White House. Before that she was chief policy officer at the America First Policy Institute, a conservative think tank.[1][4] CBS News describes her as close to Susie Wiles, the former White House chief of staff who left the job earlier this month.[2] She has not commented publicly on the withdrawal in the reports we checked.
Why the clock matters
This is the lame-duck period. Republicans hold the Senate 53 to 47 until the new Congress meets in January, when Democrats will have 56 seats to 44 after flipping nine seats in the midterms.[7] Any nominee not confirmed in this Congress has to be sent again, and Overton's chances in a Democratic Senate were seen as slim.[1] Semafor says Republicans have about a month and a half left to confirm Trump's picks, and CBS News describes a legislative window of roughly three weeks.[3][6]
That is why a senator is suddenly the name in the frame. Senators usually have an easier time getting confirmed by their colleagues, as the administration official put it to Semafor, and a senior Republican aide said Marshall's name was "quickly percolating" as someone who could be confirmed.[6] For background on the new Senate math, see our US midterm results explainer.
Who runs the FDA now, and who could be next?
For now the agency stays with Kyle Diamantas, a lawyer who was its top food official before he was named acting commissioner. Semafor says he has a reputation for steadying the agency, but he did not want the job permanently and is eyeing an exit whatever happens.[2][6]
The name most often reported is Roger Marshall, a Kansas Republican and doctor who sits on the HELP Committee and served two terms in the House before reaching the Senate in 2020. He lost his re-election race this month to Democrat Adam Hamilton. Marshall's office declined to comment to Semafor, and two sources told CBS News he was "making a play" for the post.[2][3][6]
The FDA regulates products that account for about 20% of US consumer spending, from drugs and vaccines to food, medical devices and tobacco, so the leadership gap is not just a Washington story.[2][3] The agency's recent safety calls, such as the new eye warning on GLP-1 drugs like Ozempic and Wegovy, were all made under acting leadership.
Part of a wider pattern at US health agencies
NBC News points out that the vacancy adds to a long run of upheaval at the top of federal health agencies. The Centers for Disease Control and Prevention went almost a year without a permanent director after Kennedy removed Susan Monarez only 29 days into the job last year. Trump's first pick for that role, former congressman Dave Weldon, could not win enough Republican support either, and the Senate only confirmed Dr. Erica Schwartz in August.[1] Kennedy himself faces questions from senators, as we covered in the RFK Jr. Samoa investigation.
What to watch next
- A new name: whether the White House formally nominates Marshall or someone else before the lame-duck session ends, or settles for another acting commissioner.[2][6]
- Diamantas: whether the acting commissioner stays, given the reports that he wants to leave.[6]
- Mifepristone: the FDA's safety review, due in March, will land on whoever is running the agency then.[1]
- Flavoured vapes: the policy that cost Makary his job and hurt Overton's chances is still in place.[3][5]
Frequently asked questions
Why was Heidi Overton's FDA nomination pulled?
The White House has not given a public reason. Reports point to weak support among Republicans on the Senate health committee over her handling of mifepristone and flavoured vapes. Committee chairman Bill Cassidy says she had the votes and that the White House withdrew her rather than give anti-abortion senators the assurances they wanted.[1][2][3]
Who is the FDA commissioner now?
Kyle Diamantas is acting commissioner. There has been no Senate-confirmed commissioner since Marty Makary left in May 2026.[2][6]
Was there a vote on Heidi Overton?
No. The HELP Committee vote was set for Wednesday 18 November, and the nomination was withdrawn the evening before.[1][4]
What is the Heidi Overton vape controversy?
Critics including former HHS adviser Calley Means say she wrote the White House policy that relaxed standards for fruit-flavoured vapes. Makary, her predecessor, says he was pressured to approve such products and refused.[3][5]
Who could be the next FDA commissioner?
Senator Roger Marshall of Kansas is the most reported option. The White House has also talked to people who could serve as acting commissioner without Senate confirmation.[2][6]
References
- Berkeley Lovelace Jr. and Monica Alba, NBC News, White House drops Heidi Overton's FDA nomination after Republicans raise concerns, 17 November 2026.
- CBS News, White House drops Heidi Overton's nomination for FDA commissioner, 17 November 2026.
- CBS News, Trump FDA nominee Heidi Overton struggling to win GOP support, 17 November 2026.
- Margaret Manto and Daniel Payne, STAT, White House pulls nomination of Heidi Overton to lead FDA, 17 November 2026.
- Margaret Manto and Chelsea Cirruzzo, STAT, GOP, MAHA leaders clash over FDA nominee's record on vapes, 17 November 2026.
- Burgess Everett, David Lim and Shelby Talcott, Semafor, Trump administration weighs Marshall for FDA as Overton wobbles, 17 November 2026.
- Becky Bohrer, Associated Press via Anchorage Daily News, Democrat Mary Peltola wins U.S. Senate race in Alaska, beating incumbent Republican Dan Sullivan, 17 November 2026.